In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors
for lung cancer include tobacco use, family history, radiation exposure, and the presence of …

Cisplatin-based adjuvant chemotherapy remains the standard of care for patients with
resected stage II or III non–small-cell lung cancer. However, biomarker-informed clinical …

Background Osimertinib is standard-of-care therapy for previously untreated epidermal
growth factor receptor (EGFR) mutation–positive advanced non–small-cell lung cancer …

PURPOSE ADJUVANT-CTONG1104 (ClinicalTrials. gov identifier: NCT01405079), a
randomized phase III trial, showed that adjuvant gefitinib treatment significantly improved …

Lung cancer is the leading cause of cancer mortality. It is classified into different histologic
subtypes, including adenocarcinoma, squamous carcinoma, and large cell carcinoma …

Highlights•A virtual consensus on the management of EGFR-mutant NSCLC was organized
by the ESMO, including 34 experts from 18 countries.•The experts compiled …

Importance Patients with oligometastatic non–small cell lung cancer (NSCLC) may benefit
from locally ablative therapy (LAT) such as surgery or stereotactic radiotherapy. Prior studies …

The ADJUVANT study reported the comparative superiority of adjuvant gefitinib over
chemotherapy in disease-free survival of resected EGFR-mutant stage II–IIIA non-small cell …

Objective Progress in neoadjuvant therapy for resectable nonsmall cell lung cancer (NSCLC
1) has been stagnant. There have been great achievements in immunotherapy for advanced …

The standard of care (SoC) for medically operable patients with early-stage (stage I–IIIB)
non-small cell lung cancer (NSCLC) is surgery combined with (neo) adjuvant systemic …